A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Low-dose Lurasidone in Acutely Psychotic Subjects With Schizophrenia.
Latest Information Update: 11 Aug 2023
At a glance
- Drugs Lurasidone (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Sunovion Pharmaceuticals
- 15 Sep 2020 Results (n=537) of post-hoc pooled analysis assessing safety and efficacy of Lurasidone from six double blind, placebo-controlled, 6 weeks clinical studies in adolescents and young adults with schizophrenia presented at the 33rd Annual Congress of the European College of Neuropsychopharmacology
- 08 Aug 2016 Results published in a Sunovion Pharmaceuticals media release.
- 08 Aug 2016 Results published in the Journal of Clinical Psychiatry, according to a Sunovion Pharmaceuticals media release.